Ask AI
Back Back
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Peter Lio
Peter Lio, MD, FAAD
Activity Information

Activity

Progress
1
Course Completed

Outcome: Case Conclusion
Jeremy continues tralokinumab at 300 mg every 2 weeks with regular follow-ups every 3-6 months. His symptoms remain well-controlled, with a consistently low EASI score and minimal itch severity (2/10). He maintains uninterrupted sleep, high energy levels, and improved emotional well-being. By adhering to the treatment plan, Jeremy successfully prevents flare-ups and sustains his quality of life, confidently engaging in social and physical activities without limitations. Regular follow-ups ensure monitoring of his progress, early identification of potential issues, and reinforcement of his treatment adherence, solidifying long-term control of his AD.

Discussion Summary 
AD is a chronic inflammatory condition that significantly affects patients’ quality of life. Advances in understanding its immunopathogenesis have revealed IL-13 as a key driver of disease activity. IL-13 contributes to skin barrier dysfunction by impairing the expression of essential proteins like filaggrin, promotes T helper 2–mediated inflammation, and perpetuates the chronicity of AD.1

Targeting IL-13 with biologic therapies such as tralokinumab and lebrikizumab has proven highly effective. Clinical trials, including ECZTRA-1 and ECZTRA-2, demonstrate that tralokinumab significantly reduces symptom severity, improves skin clearance as measured by EASI scores, and alleviates pruritus, which is a major source of distress for patients.2 In the ADvocate 1 and 2 clinical trials, lebrikizumab demonstrated significant efficacy and a generally favorable safety profile in the treatment of moderate to severe AD. Lebrikizumab improved EASI across all body regions, with improvements seen as early as Week 2 in both studies. At Week 16, lebrikizumab significantly improved EASI compared with placebo across all body regions.3

In LIBERTY AD clinical study, dupilumab, an IL-4/IL-13 inhibitor, has shown substantial improvements in AD symptoms, and quality of life for patients with moderate to severe disease. Although dupilumab has been generally well-tolerated, some adverse events, including conjunctivitis and injection-site reactions, have been observed more frequently in the dupilumab treatment groups compared with placebo.4,5

Unlike conventional therapies such as topical corticosteroids or systemic immunosuppressants, IL-13 inhibitors such as tralokinumab and lebrikizumab offer targeted and sustained control without the significant adverse effects associated with long-term corticosteroid use. This is particularly critical for patients with moderate to severe AD, as seen in Jeremy's case, where the chronic and recurrent nature of the disease necessitates ongoing management.6

Patient-centered care plays a pivotal role in maximizing outcomes. Educating patients about the chronicity of AD, the importance of adherence to biologic therapy, and realistic expectations ensures better treatment engagement. Complementary strategies such as trigger avoidance, consistent moisturizing routines, and stress management enhance the effectiveness of biologics. Regular follow-ups are vital for monitoring treatment efficacy, addressing potential adverse effects, and maintaining patient confidence.7

Jeremy’s positive response to tralokinumab highlights the transformative impact of biologic therapy on AD management, offering a significant improvement in symptoms, quality of life, and long-term disease control while emphasizing the need for a comprehensive, personalized approach to care.